Gribble FM, Reimann F (2021) Metabolic messengers: glucagon-like peptide 1. Nat Metab 3(2):142–148. https://doi.org/10.1038/s42255-020-00327-x

Article  CAS  PubMed  Google Scholar 

Meier JJ (2012) GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8(12):728–742. https://doi.org/10.1038/nrendo.2012.140

Article  CAS  PubMed  Google Scholar 

Lafferty RA, Flatt PR, Irwin N (2023) GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy. Expert Opin Pharmacother 24(5):587–597. https://doi.org/10.1080/14656566.2023.2192865

Article  CAS  PubMed  Google Scholar 

Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87(4):1409–1439. https://doi.org/10.1152/physrev.00034.2006

Article  CAS  PubMed  Google Scholar 

Sandoval DA, D’Alessio DA (2015) Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev 95(2):513–548. https://doi.org/10.1152/physrev.00013.2014

Article  CAS  PubMed  Google Scholar 

Smith NK, Hackett TA, Galli A, Flynn CR (2019) GLP-1: molecular mechanisms and outcomes of a complex signaling system. Neurochem Int 128:94–105. https://doi.org/10.1016/j.neuint.2019.04.010

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kopp KO, Glotfelty EJ, Li Y, Greig NH (2022) Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment. Pharmacol Res 186:106550. https://doi.org/10.1016/j.phrs.2022.106550

Article  CAS  PubMed  PubMed Central  Google Scholar 

Imbriani P, Martella G, Bonsi P, Pisani A (2022) Oxidative stress and synaptic dysfunction in rodent models of Parkinson’s disease. Neurobiol Dis 173:105851. https://doi.org/10.1016/j.nbd.2022.105851

Article  CAS  PubMed  Google Scholar 

Heidari A, Yazdanpanah N, Rezaei N (2022) The role of toll-like receptors and neuroinflammation in Parkinson’s disease. J Neuroinflammation 19(1):135. https://doi.org/10.1186/s12974-022-02496-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Athauda D, Foltynie T (2016) The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson’s disease: mechanisms of action. Drug Discov Today 21:802–818. https://doi.org/10.1016/j.drudis.2016.01.013

Article  CAS  PubMed  Google Scholar 

Kim DS, Choi HI, Wang Y, Luo Y, Hoffer BJ, Greig NH (2017) A new treatment strategy for Parkinson’s disease through the gut-brain axis: the glucagon-like peptide-1 receptor pathway. Cell Transpl 26:1560–1571. https://doi.org/10.1177/0963689717721234

Article  Google Scholar 

Zheng J, Xie Y, Ren L, Qi L, Wu L, Pan X et al (2021) GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer’s disease. Mol Metab 47:101180. https://doi.org/10.1016/j.molmet.2021.101180

Article  CAS  PubMed  PubMed Central  Google Scholar 

Du H, Meng X, Yao Y, Xu J (2022) The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease. Front Endocrinol (Lausanne) 13:1033479. https://doi.org/10.3389/fendo.2022.1033479

Article  PubMed  PubMed Central  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 29:372:n71. https://doi.org/10.1136/bmj.n71

Article  Google Scholar 

Meurot C, Martin C, Sudre L, Breton J, Bougault C, Rattenbach R et al (2022) Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis. Sci Rep 12(1):1567. https://doi.org/10.1038/s41598-022-05323-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mert I, Cetinkaya A, Gurler M, Turel CA, Celik H, Torun IE et al (2022) Anti-inflammatory potential of liraglutide, a glucagon-like peptide-1 receptor agonist, in rats with peripheral acute inflammation. Inflammopharmacology 30(3):1093–1105. https://doi.org/10.1007/s10787-022-00978-0

Article  CAS  PubMed  Google Scholar 

Fan H, Gong N, Li TF, Ma AN, Wu XY, Wang MW et al (2015) The non-peptide GLP-1 receptor agonist WB4-24 blocks inflammatory nociception by stimulating β-endorphin release from spinal microglia. Br J Pharmacol 172(1):64–79. https://doi.org/10.1111/bph.12895

Article  CAS  PubMed  Google Scholar 

Cho PG, Jang JH, Ko S, Shin DA, Chung S, Chang MC (2023) The effect of evogliptin tartrate on controlling inflammatory pain. Biomedicines 11(11):2990. https://doi.org/10.3390/biomedicines11112990

Article  CAS  PubMed  PubMed Central  Google Scholar 

Balogh M, Varga BK, Karádi DÁ, Riba P, Puskár Z, Kozsurek M et al (2019) Similarity and dissimilarity in antinociceptive effects of dipeptidyl-peptidase 4 inhibitors, Diprotin A and vildagliptin in rat inflammatory pain models following spinal administration. Brain Res Bull 147:78–85. https://doi.org/10.1016/j.brainresbull.2019.02.001

Article  CAS  PubMed  Google Scholar 

Aykan DA, Kesim M, Ayan B, Kurt A (2019) Anti-inflammatory and antinociceptive activities of glucagon-like peptides: evaluation of their actions on serotonergic, nitrergic, and opioidergic systems. Psychopharmacology 236(6):1717–1728. https://doi.org/10.1007/s00213-018-5154-7

Article  CAS  PubMed  Google Scholar 

Gudbergsen H, Overgaard A, Henriksen M, Wæhrens EE, Bliddal H, Christensen R et al (2021) Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. Am J Clin Nutr 113(2):314–323. https://doi.org/10.1093/ajcn/nqaa328

Article  CAS  PubMed  Google Scholar 

Zhu H, Zhou L, Wang Q, Cai Q, Yang F, Jin H et al (2023) Glucagon-like peptide-1 receptor agonists as a disease-modifying therapy for knee osteoarthritis mediated by weight loss: findings from the Shanghai Osteoarthritis Cohort. Ann Rheum Dis 82(9):1218–1226. https://doi.org/10.1136/ard-2023-223845

Article  CAS  PubMed  Google Scholar 

Jing F, Zou Q, Wang Y, Cai Z, Tang Y (2021) Activation of microglial GLP-1R in the trigeminal nucleus caudalis suppresses central sensitization of chronic migraine after recurrent nitroglycerin stimulation. J Headache Pain 22(1):86. https://doi.org/10.1186/s10194-021-01302-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jing F, Zou Q, Pu Y (2023) GLP-1R agonist liraglutide attenuates pain hypersensitivity by stimulating IL-10 release in a nitroglycerin-induced chronic migraine mouse model. Neurosci Lett 812:137397. https://doi.org/10.1016/j.neulet.2023.137397

Article  CAS  PubMed  Google Scholar 

Botfield HF, Uldall MS, Westgate CSJ, Mitchell JL, Hagen SM, Gonzalez AM et al (2017) A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus. Sci Transl Med 9(404):eaan0972. https://doi.org/10.1126/scitranslmed.aan0972

Article  CAS  PubMed  Google Scholar 

Krajnc N, Itariu B, Macher S, Marik W, Harreiter J, Michl M et al (2023) Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension. J Headache Pain 24(1):89. https://doi.org/10.1186/s10194-023-01631-z

Article  CAS  PubMed  PubMed Central